Omega 3 Prescription Drugs Market Report 2026

Omega 3 Prescription Drugs Market Overview

• Omega 3 Prescription Drugs market size has reached to $1.75 billion in 2025 • Expected to grow to $2.81 billion in 2030 at a compound annual growth rate (CAGR) of 10% • Growth Driver: Omega-3-global-market-report" target="_blank">Omega-3 Prescription Drug Market Growth Tied To Cardiovascular Disease Surge • Market Trend: Innovation In Omega-3 Prescription Drugs With Icosapent Ethyl Capsules Drives Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Omega 3 Prescription Drugs Market?

The omega-3 prescription drug lowers the number of triglycerides (a fat-like substance) in the blood and raises the levels of good cholesterol (HDL) in the body. Omega-3 drugs or fatty acids are nutrients obtained from food (or supplements) that assist in developing and maintaining a healthy body and are critical in constructing every cell wall. The main drug types of omega-3 prescription drugs include vascepa, lovaza, and other types. The vascepa drug is used in adults to reduce the risk of heart attack, stroke, and certain types of heart problems that necessitate hospitalization. Vascepa is an FDA-approved medication used to reduce the risk of certain cardiovascular problems in adults who have high triglyceride levels and two or more additional risk factors for cardiovascular diseases, such as high blood pressure, high cholesterol, or obesity. The application of omega-3 prescription drugs includes hypertriglyceridemia and other application types. The drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Omega 3 Prescription Drugs Market Growth Forecast?

The omega 3 prescription drugs market size is expected to see strong growth in the next few years. It will grow to $2.81 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to advancements in precision medicine, rising demand for personalized therapies, integration of digital health tools, expansion in emerging markets, innovation in omega-3 drug formulations. Major trends in the forecast period include personalized omega-3 therapy development, increased clinical trials for omega-3 formulations, growth in cardiovascular risk management solutions, expansion of prescription omega-3 drug accessibility, enhanced nutraceutical-pharmaceutical integration.

Global Omega 3 Prescription Drugs Market Segmentation

1) By Drug Type: Vascepa, Lovaza, Other Type 2) By Application Type: Hypertriglyceridemia, Other Application Type 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Vascepa: Pure EPA (Eicosapentaenoic Acid) Formulation, Indications For Cardiovascular Risk Reduction 2) By Lovaza: Combination Of EPA And DHA (Docosahexaenoic Acid), Indications For Hypertriglyceridemia Management 3) By Other Types: Epanova (Omega-3 Carboxylic Acids), Omega-3 Formulations In Clinical Trials, Other Prescription Omega-3 Products

What Is The Driver Of The Omega 3 Prescription Drugs Market?

Rising cases of cardiovascular diseases (CVDs) are expected to contribute to the growth of the omega-3 prescription drug market. Increased blood triglyceride levels (a fatty-like substance) are linked to a higher risk of cardiovascular disorders, and omega-3 supplements aid in regulating and lowering triglyceride levels. For instance, in August 2025, according to the National Institutes of Health, a US-based government agency, between 2025 and 2050, cardiovascular prevalence is projected to rise by 90%, mortality by 73%, and DALYs by 55%, with deaths increasing from 20.5 million to 35.6 million. Therefore, rising cases of cardiovascular diseases (CVDs) drive the growth of the omega-3 prescription drug market.

Key Players In The Global Omega 3 Prescription Drugs Market

Major companies operating in the omega 3 prescription drugs market are Pfizer Inc., Sanofi S.A., Amarin Corporation plc, GlaxoSmithKline plc, AstraZeneca plc, Merck & Co. Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, BASF SE, DSM Nutritional Products, AbbVie Inc., Eli Lilly and Company, Bayer AG, Shire Pharmaceuticals, Mylan NV, Teva Pharmaceutical Industries Ltd., Horizon Therapeutics, Kyowa Kirin Co. Ltd., Sumitomo Pharma Co. Ltd.

Global Omega 3 Prescription Drugs Market Trends and Insights

Major companies operating in the omega-3 prescription drug market are focusing on product launches, such as capsules, to work by decreasing the number of triglycerides made by the body. Capsules are pharmaceutical or dietary supplement dosage forms consisting of a shell typically made of gelatin or a similar substance enclosing a specific quantity of medication, nutrients, or other active ingredients in a convenient and easily ingestible form. For instance, in March 2023, Hikma Pharmaceuticals, an England-based multinational pharmaceutical company that manufactures generic and in-licensed pharmaceutical products, launched Icosapent Ethyl Capsules, 0.5g, in the US. This is indicated for reducing triglyceride levels in adults with severe hypertriglyceridemia, containing eicosatetraenoic acid (EPA) known for its triglyceride-lowering effects. This launch innovates the market by addressing severe hypertriglyceridemia, meeting the rising demand for pharmaceutical-grade omega-3 products, and aligning with the market's focus on effective therapies for conditions like high triglyceride levels.

What Are Latest Mergers And Acquisitions In The Omega 3 Prescription Drugs Market?

In July 2024, KD Pharma, a Europe-based contract development and manufacturing organization (CDMO) specializing in pharmaceutical and nutritional lipids has acquired DSM-Firmenich's MEG-3 fish oil business, including production facilities in Peru and Canada, along with around 200 employees for an undisclosed amount. This strategic move allows KD Pharma to expand its presence in the food, beverage, dietary supplement, and pharmaceutical markets. DSM-Firmenich, a Europe-based and MEG-3 business are connected to omega-3 products.

Regional Insights

North America was the largest region in the omega 3 prescription drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Omega 3 Prescription Drugs Market?

The omega 3 prescription drugs market consists of sales of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Omega 3 Prescription Drugs Market Report 2026?

The omega 3 prescription drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the omega 3 prescription drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.